Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| NTLA | Intellia Therapeutics, Inc. | 2026-03-03 06:16:18 | 14.48 | -0.96 | -6.22 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NTLA | 0001652130 | Intellia Therapeutics, Inc. | US45826J1051 | 5493002T5BCPE5DZC723 | 364785571 | Nasdaq | 2835 | In Vitro & In Vivo Diagnostic Substances | 1231 | DE | 40 ERIE STREET | CAMBRIDGE | MA | 02139 | UNITED STATES | US | 857-285-6200 | 40 ERIE STREET, CAMBRIDGE, MA, 02139 | 40 ERIE STREET, CAMBRIDGE, MA, 02139 | — | Biotherapeutics | 2014 | John Leonard | 598 | http://intelliatx.com | 1,916,954,312 | 115,787,285 | 115,829,926 | Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. | 2026-02-26 17:39:32 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 869,490,759 | -1,047,463,553 | -54.6421 | 118,133,546 | 14,616,086 | 14.1194 |
| 2024 | 1,916,954,312 | -1,648,117,376 | -46.2296 | 103,517,460 | 7,411,055 | 7.7113 |
| 2023 | 3,565,071,688 | -324,002,575 | -8.3311 | 96,106,405 | 8,088,466 | 9.1896 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| James Basta, J.D. | Corporate Secretary, Executive Vice President, General Counsel | 2024 | 479,000 | 166,185 | 3,159,208 | — | 11,097 | 4,872,670 |
| David Lebwohl, M.D. | Chief Medical Officer, Executive Vice President | 2024 | 520,000 | 201,552 | 3,581,737 | — | 11,097 | 5,577,407 |
| John M. Leonard | Chief Executive Officer, President | 2024 | 687,000 | 424,223 | 10,488,027 | — | 24,452 | 15,330,547 |
| Edward J. Dulac | Chief Financial Officer, Treasurer, Executive Vice President | 2024 | 228,192 | 303,490 | 4,460,028 | — | 24,005 | 6,694,737 |
| Laura Sepp-Lorenzino, Ph.D. | Chief Scientific Officer, Executive Vice President | 2024 | 512,000 | 184,832 | 3,533,439 | — | 35,850 | 5,505,150 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 377 |
| 2024 | 403 |
| 2023 | 526 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 67,671,000 | 57,877,000 | 6,600,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 388,861,000 | 466,311,000 | 435,069,000 |
| General And Administrative Expenses | 119,800,000 | 125,829,000 | 116,497,000 |
| Operating Expenses | 508,661,000 | 592,140,000 | 551,566,000 |
| Operating Income | -440,990,000 | -534,263,000 | -515,291,000 |
| Net Income | -412,694,000 | -519,021,000 | -481,192,000 |
| Earnings Per Share Basic | -3.81 | -5.25 | -5.42 |
| Earnings Per Share Diluted | -3.81 | -5.25 | -5.42 |
| Weighted Average Shares Outstanding Basic | 108,376,000 | 98,849,000 | 88,770,000 |
| Weighted Average Shares Outstanding Diluted | 108,376,000 | 98,849,000 | 88,770,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 12,104,000 | 13,605,000 | 13,605,000 |
| Marketable Securities Current | 294,420,000 | 412,333,000 | 685,475,000 |
| Accounts Receivable | 9,468,000 | 8,517,000 | 36,456,000 |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 527,711,000 | 639,863,000 | 998,330,000 |
| Marketable Securities Non Current | 155,250,000 | 260,215,000 | 99,864,000 |
| Property Plant And Equipment | 17,671,000 | 27,381,000 | 32,760,000 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | 314,416,000 | 551,152,000 | 302,647,000 |
| Total Assets | 842,127,000 | 1,191,015,000 | 1,300,977,000 |
| Accounts Payable | 20,252,000 | 14,589,000 | 7,452,000 |
| Deferred Revenue | 7,290,000 | 20,661,000 | 22,140,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 49,862,000 | 55,355,000 | 67,017,000 |
| Total Liabilities Current | 103,884,000 | 110,851,000 | 115,208,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 66,849,000 | 208,208,000 | 135,600,000 |
| Total Liabilities | 170,733,000 | 319,059,000 | 250,808,000 |
| Common Stock | 12,000 | 10,000 | 9,000 |
| Retained Earnings | -2,590,094,000 | -2,177,400,000 | -1,658,379,000 |
| Accumulated Other Comprehensive Income | 1,032,000 | 605,000 | -2,258,000 |
| Total Shareholders Equity | 671,394,000 | 871,956,000 | 1,050,169,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 9,767,000 | 10,285,000 | 8,976,000 |
| Share Based Compensation Expense | 80,219,000 | 154,273,000 | 134,050,000 |
| Other Non Cash Income Expense | -527,000 | 76,000 | -72,000 |
| Change In Accounts Receivable | 951,000 | -27,939,000 | 32,688,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | -2,811,000 | -917,000 | 707,000 |
| Change In Accounts Payable | 5,987,000 | 6,800,000 | 2,522,000 |
| Change In Other Liabilities | -5,271,000 | -10,383,000 | 6,024,000 |
| Cash From Operating Activities | -394,736,000 | -348,880,000 | -394,086,000 |
| Purchases Of Marketable Securities | 322,510,000 | 935,573,000 | 904,464,000 |
| Sales Of Marketable Securities | 551,670,000 | 1,066,918,000 | 887,102,000 |
| Acquisition Of Property Plant And Equipment | 1,129,000 | 5,778,000 | 13,985,000 |
| Acquisition Of Business | — | 287,000 | 287,000 |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 228,031,000 | 125,567,000 | -31,347,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 128,175,000 | 2,986,000 | 3,929,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 131,486,000 | 185,747,000 | 130,323,000 |
| Change In Cash | -35,219,000 | -37,566,000 | -295,110,000 |
| Cash At End Of Period | 12,104,000 | 13,605,000 | 13,605,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | — | — | — |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -3.81 | -5.25 | -5.42 |
| Price To Earnings Ratio | -2.3596 | -2.221 | -5.6255 |
| Earnings Growth Rate | -27.4286 | -3.1365 | -12.013 |
| Price Earnings To Growth Ratio | 0.086 | 0.7081 | 0.4683 |
| Book Value Per Share | 6.195 | 8.8211 | 11.8302 |
| Price To Book Ratio | 1.4512 | 1.3218 | 2.5773 |
| Ebitda | -402,927,000 | -508,736,000 | -472,216,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 57,000 | 4,906,000 | 13,815,000 |
| Free Cash Flow | -394,793,000 | -353,786,000 | -407,901,000 |
| Return On Equity | -0.6147 | -0.5952 | -0.4582 |
| One Year Beta | 1.518 | 2.0896 | 1.9472 |
| Three Year Beta | 1.7399 | 2.083 | 2.1395 |
| Five Year Beta | 1.9674 | 1.7438 | 1.7647 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Dube Michael P | VP, Chief Accounting Officer | 2026-01-05 | 2,989 | D | 52,277 |
| Dulac Edward J III | EVP, Chief Financial Officer | 2026-01-05 | 6,379 | D | 99,683 |
| Clark Eliana | EVP, Chief Technical Officer | 2026-01-05 | 9,515 | D | 87,118 |
| Lebwohl David | EVP, Chief Medical Officer | 2026-01-05 | 11,903 | D | 121,249 |
| Cohen Fred E | Director | 2026-01-05 | 150,000 | A | 207,453 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Thomas R Carper | Senator | 2023-09-05 | Sale (Full) | 2023-08-25 | Spouse | $1,001 - $15,000 |
| Thomas R Carper | Senator | 2023-06-30 | Purchase | 2023-05-22 | Spouse | $1,001 - $15,000 |
| Thomas R Carper | Senator | 2020-12-02 | Purchase | 2020-11-20 | Spouse | $1,001 - $15,000 |
| James M Inhofe | Senator | 2018-11-08 | Sale (Full) | 2018-10-25 | Self | $15,001 - $50,000 |
| James M Inhofe | Senator | 2017-11-08 | Purchase | 2017-10-19 | Self | $15,001 - $50,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Donald Sternoff Honorable Beyer | 2021-08-07 | VA08 | Sale | 2021-07-21 | Joint | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Caitong International Asset Management Co., Ltd | 2025-12-31 | 54 | 6 | 9 |
| MV CAPITAL MANAGEMENT, INC. | 2025-12-31 | 486 | 54 | 9 |
| Virtu Financial LLC | 2025-12-31 | 245,000 | 27,260 | 8.9875 |
| Invesco Ltd. | 2025-12-31 | 3,895,277 | 433,290 | 8.99 |
| AXXCESS WEALTH MANAGEMENT, LLC | 2025-12-31 | 192,378 | 21,399 | 8.99 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| RYDEX SERIES FUNDS | 2025-12-31 | Class C | RYCFX | 48,347 | 434,639.53 | 0.3987 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class A | RYBOX | 48,347 | 434,639.53 | 0.3987 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class H | RYOAX | 48,347 | 434,639.53 | 0.3987 |
| RYDEX SERIES FUNDS | 2025-12-31 | Investor Class | RYOIX | 48,347 | 434,639.53 | 0.3987 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class C | RYCMX | 138 | 1,240.62 | 0.0147 |